United states securities and exchange commission

Table of Contents
92
PART III
Item 10.      Directors, Executive Officers 
and Corporate Governance
The information concerning our executive 
officers is set forth under the heading “Our Executive 
Officers” in Item 1 of this report. The text of our code 
of business conduct, which includes the code of 
ethics that applies to our principal executive officer, 
principal financial officer, principal accounting officer 
or controller, and persons performing similar 
functions, is posted on our website, www.biogen.com, 
under the “Governance” subsection of the “About Us” 
section of the site. We intend to make all required 
disclosures regarding any amendments to, or waivers 
from, provisions of our code of business conduct at 
the same location of our website. 
The response to the remainder of this item is 
incorporated by reference from the discussion 
responsive thereto in the sections entitled 
“Proposal 1 - Election of Directors,” “Corporate 
Governance at Biogen,” “Stock Ownership - 
Section 16(a) Beneficial Ownership Reporting 
Compliance” and “Miscellaneous - Stockholder 
Proposals” contained in the proxy statement for our 
2018 annual meeting of stockholders.
Item 11.      Executive Compensation
The response to this item is incorporated by 
reference from the discussion responsive thereto in 
the sections entitled “Executive Compensation 
Matters” and “Corporate Governance at Biogen” 
contained in the proxy statement for our 2018 annual 
meeting of stockholders.
Item 12.      Security Ownership of Certain 
Beneficial Owners and Management and 
Related Stockholder Matters
The response to this item is incorporated by 
reference from the discussion responsive thereto in 
the sections entitled “Stock Ownership” and “Equity 
Compensation Plan Information” contained in the proxy 
statement for our 2018 annual meeting of 
stockholders.
Item 13.      Certain Relationships and 
Related Transactions, and Director 
Independence
The response to this item is incorporated by 
reference from the discussion responsive thereto in 
the sections entitled “Certain Relationships and 
Related Person Transactions” and “Corporate 
Governance at Biogen” contained in the proxy 
statement for our 2018 annual meeting of 
stockholders.
Item 14.      Principal Accounting Fees and 
Services
The response to this item is incorporated by 
reference from the discussion responsive thereto in 
the section entitled “Proposal 2 — Ratification of the 
Selection of our Independent Registered Public 
Accounting Firm” contained in the proxy statement for 
our 2018 annual meeting of stockholders.

---

Table of Contents
93
PART IV
Item 15.  
Exhibits and Financial Statement Schedules
a.   (1) Consolidated Financial Statements:
The following financial statements are filed as part of this report:
Financial Statements
Page Number
Consolidated Statements of Income
F-2
Consolidated Statements of Comprehensive Income
F-3
Consolidated Balance Sheets
F-4
Consolidated Statements of Cash Flows
F-5
Consolidated Statements of Equity
F-6
Notes to Consolidated Financial Statements
F-9
Report of Independent Registered Public Accounting Firm
F-77
Certain totals may not sum due to rounding.
  
(2) Exhibits
The exhibits listed on the Exhibit Index beginning on page 94, which is incorporated herein by reference, are 
filed or furnished as part of this report or are incorporated into this report by reference.
 
(3) Financial Statement Schedules
Schedules are omitted because they are not applicable, or are not required, or because the information is 
included in the consolidated financial statements and notes thereto.
Item 16.  
Form 10-K Summary
Not applicable.

---

Table of Contents
94
EXHIBIT INDEX
Exhibit No.
  
Description
2.1†
Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma 
International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed 
as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.
2.2
Separation Agreement between Biogen Inc. and Bioverativ Inc. dated as of January 31, 
2017. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.
3.1
  
Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to 
our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.
3.2
Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our 
Current Report on Form 8-K filed on March 27, 2015.
3.3
  
Fourth Amended and Restated Bylaws. Filed as Exhibit 3.1 to our Current Report on Form 
8-K filed on June 9, 2017.
4.1
  
Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges 
of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.
4.2
Indenture between Biogen Inc. and U.S. Bank National Association, dated as of September 
15, 2015. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 
2015.
4.3
First Supplemental Indenture between Biogen Inc. and U.S. Bank National Association, 
dated September 15, 2015. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed 
on September 16, 2015.
10.1
  
Credit Agreement between Biogen Inc., Bank of America, N.A., Goldman Sachs Bank USA 
and other lenders party thereto, dated August 28, 2015. Filed as Exhibit 10.1 to our Current 
Report on Form 8-K filed on September 1, 2015.
10.2†
  
Second Amended and Restated Collaboration Agreement between Biogen Idec Inc. and 
Genentech, Inc., dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report 
on Form 10-K for the year ended December 31, 2010.
10.3†
  
Letter  Agreement  regarding  GA101  financial  terms  between  Biogen  Idec  Inc.  and 
Genentech, Inc., dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on 
Form 10-K for the year ended December 31, 2010.
10.4
Settlement  and  License  Agreement,  dated  January  17,  2017,  between  Biogen  Swiss 
Manufacturing GmbH, Biogen International Holdings ltd., Forward Pharma A/S and other 
parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 
1, 2017.
10.5*
  
Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix B to our Definitive Proxy Statement 
on Schedule 14A filed on April 26, 2017.
10.6*
  
Form of restricted stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity 
Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended 
June 30, 2017.
10.7*
Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity 
Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended 
June 30, 2017.
10.8*
  
Form of performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity 
Plan. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended 
June 30, 2017.
10.9*
  
Form  of  cash-settled  performance  unit  award  agreement  under  the  Biogen  Inc.  2017 
Omnibus Equity Plan. Filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q for the 
quarter ended June 30, 2017.
10.10*+
  
Form of performance stock units award agreement (cash-settled) under the Biogen Inc. 
2017 Omnibus Equity Plan.
10.11*+
Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus 
Equity Plan.
10.12*
  
Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 
to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.
10.13*
  
Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus 
Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter 
ended March 31, 2014.

---